Inventor · disambiguated record
Sudeesh K. Tantry
Also filed as: TANTRY SUDEESH K
9 granted patents·2 pending applications·5 citations·filing 2014–2025
79Inventor score
Top patents by PatentIndex Score
11 records- 0191US12303635B2Dispensing device and pharmaceutical composition for the treatment of rhinitisGLENMARK SPECIALTY SA·Filed 2023·Granted May 20, 2025·1 cites·10 claims
- 0282US10016443B2Treatment of allergic rhinitis using a combination of mometasone and olopatadineGLENMARK SPECIALTY SA·Filed 2017·Granted Jul 10, 2018·2 cites·24 claims
- 0381US2024156840A1Treatment of allergic rhinitis using a combination of mometasone and olopatadineGLENMARK SPECIALTY SA·Filed 2023·Application pending·0 cites
- 0478US12064442B2Treatment of allergic rhinitis using a combination of mometasone and olopatadineGLENMARK SPECIALTY SA·Filed 2022·Granted Aug 20, 2024·0 cites·18 claims
- 0571US10548907B2Treatment of allergic rhinitis using a combination of mometasone and olopatadineGLENMARK PHARMACEUTICALS LTD·Filed 2015·Granted Feb 4, 2020·1 cites·32 claims
- 0670US11400101B2Treatment of allergic rhinitis using a combination of mometasone and olopatadineGLENMARK SPECIALTY SA·Filed 2020·Granted Aug 2, 2022·0 cites·26 claims
- 0767US11679210B2Dispensing device and pharmaceutical composition for the treatment of rhinitisGLENMARK SPECIALTY SA·Filed 2018·Granted Jun 20, 2023·1 cites·16 claims
- 0864US2025242115A1Dispensing device and pharmaceutical composition for the treatment of rhinitisGLENMARK SPECIALTY SA·Filed 2025·Application pending·0 cites
- 0958US10758550B2Treatment of allergic rhinitis using a combination of mometasone and olopatadineGLENMARK SPECIALTY SA·Filed 2018·Granted Sep 1, 2020·0 cites·32 claims
- 1055US10646500B2Treatment of allergic rhinitis using a combination of mometasone and olopatadineGLENMARK PHARMACEUTICALS LTD·Filed 2014·Granted May 12, 2020·0 cites·15 claims
- 1150US10653661B2Treatment of allergic rhinitis using a combination of mometasone and olopatadineGLENMARK SPECIALTY SA·Filed 2017·Granted May 19, 2020·0 cites·5 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →